← All trials
NCT07253207
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2024
- Primary completion
- Jun 13, 2025
- Completion date
- Jul 22, 2025
- First posted
- Nov 28, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 392
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang Huahai Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.